NCT00025506 · OUTCOME

Initial Histologic Grade

Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline

What was measured

G3 - Predominantly solid or entirely undifferentiated carcinoma. Not graded - tumor grade not reported.

Analysis population: Eligible and evaluable patients

Groups in this outcome

Thalidomide

Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Thalidomide	45

Reported measurements

Source class 1

Grade 3

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Thalidomide	4	Not reported	Not reported	Not reported	Not reported

Not graded

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Thalidomide	41	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4
title
Grade 3
measurements
group Id
OG000
value
41
title
Not graded

denoms

counts
group Id
OG000
value
45
units
Participants

description

G3 - Predominantly solid or entirely undifferentiated carcinoma. Not graded - tumor grade not reported.

groups

description
Thalidomide 200 mg PO once a day initial dose (each 28-day period will be considered one cycle). Dose increased by 200 mg every 2 weeks to maximum dose of 1000 mg/day until disease progression or adverse effects prohibit further therapy.
id
OG000
title
Thalidomide

param Type

COUNT_OF_PARTICIPANTS

population Description

Eligible and evaluable patients

reporting Status

POSTED

time Frame

Baseline

title

Initial Histologic Grade

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice